{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:22:30Z","timestamp":1788362550543,"version":"build-2803163510"},"reference-count":57,"publisher":"American Medical Association (AMA)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"abstract":"\n Importance<\/jats:title>\n Pleomorphic dermal sarcomas (PDSs) are classified as sarcomas; however, they share features with cutaneous carcinomas, such as presentation on sun-exposed areas and high tumor mutational burden (TMB). Data regarding management of PDS are limited, and it is unclear whether sarcoma or cutaneous cancer treatment paradigms should apply. At present, there are no published data comparing the mutational genetics of PDSs to other cutaneous tumors and to other soft-tissue sarcomas (STSs).<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare TMB, UV signature, and single-nucleotide and pathway-level mutational profiles of PDS to cutaneous squamous cell carcinoma (CSCC) and STS.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This single-center retrospective cohort study was performed at the Dana-Farber Cancer Institute and Brigham and Women\u2019s Hospital from January 1, 2015, to October 20, 2025. Patients diagnosed with PDS, metastatic CSCC, and STS were identified by electronic medical records and included if a 447-tumor gene sequencing assay was performed on tumor tissue.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point was to compare the single-nucleotide variant profiles of PDS, metastatic CSCC, and STS using unsupervised machine learning analysis. The secondary end points were to compare mean TMB, pathway-level mutations, and UV signature status.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 9 PDSs, 15 metastatic CSCCs, and 25 STSs were included. At the pathway level,\n TP53<\/jats:italic>\n , cell cycle,\n NOTCH<\/jats:italic>\n , and receptor tyrosine kinase\u2013Ras pathways were highly mutated in PDS and CSCC, whereas STS lacked major pathway mutations. The mean TMB was 44.6 (95% CI, 37.5-51.8) for PDS, 54.1 (95% CI, 40.4-67.8) for CSCC, and 4.2 (95% CI, 3.2-5.2) for STS. Statistically significant differences in mean TMB were observed between CSCC and STS and between PDS and STS but not between CSCC and PDS. All PDSs and CSCCs displayed UV signature mutations, while none of other STSs did. Principal component analysis of mutational variants and TMB on sequencing assay showed completely overlapping PDS and CSCC clusters and separate, narrow STS clustering.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study, PCA analysis of single-nucleotide variants and comparison of TMB, UV signature, and pathway-level alterations between groups suggested similar genetic profiling between metastatic CSCC and PDS, which were distinct from STS.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2026.3297","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:00:25Z","timestamp":1788361225000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparison of Pleomorphic Dermal Sarcoma to Advanced Cutaneous Squamous Cell Carcinoma and Soft-Tissue Sarcoma"],"prefix":"10.1001","author":[{"given":"Haley","family":"Neff","sequence":"first","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Mortelliti","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bina","family":"Kassamali","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Lotter","sequence":"additional","affiliation":[{"name":"Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Hanrahan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Solomon","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Karn","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole R.","family":"LeBoeuf","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Center for Cutaneous Oncology, Department of Dermatology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Department of Orthopedic Surgery, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Gusev","sequence":"additional","affiliation":[{"name":"Division of Genetics, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Ready","sequence":"additional","affiliation":[{"name":"Division of Genetics, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Department of Orthopedic Surgery, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod E.","family":"Nambudiri","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Center for Cutaneous Oncology, Department of Dermatology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina A.","family":"Ran","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Center for Cutaneous Oncology, Department of Dermatology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann W.","family":"Silk","sequence":"additional","affiliation":[{"name":"Center for Cutaneous Oncology, Department of Dermatology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily S.","family":"Ruiz","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Center for Cutaneous Oncology, Department of Dermatology, Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"issue":"6","key":"doi260040r1","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.jaad.2023.08.050","article-title":"Atypical fibroxanthoma and pleomorphic dermal sarcoma: local recurrence and metastasis in a nationwide population-based cohort of 1118 patients.","volume":"89","author":"\u00d8rholt","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi260040r2","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1684\/ejd.2020.3875","article-title":"Pleomorphic dermal sarcoma: a retrospective study of 16 cases in a dermato-oncology centre and a review of the literature.","volume":"30","author":"R\u00edos-Vi\u00f1uela","year":"2020","journal-title":"Eur J Dermatol"},{"key":"doi260040r3","doi-asserted-by":"publisher","DOI":"10.1111\/ans.70748","article-title":"Systematic review comparing wide local excision and Mohs micrographic surgery for pleomorphic dermal sarcoma.","author":"Sivieng","year":"2026","journal-title":"ANZ J Surg"},{"issue":"8","key":"doi260040r4","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1586\/era.09.76","article-title":"MFH classification: differentiating undifferentiated pleomorphic sarcoma in the 21st Century.","volume":"9","author":"Matushansky","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6","key":"doi260040r5","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.5858\/2008-132-1030-MFHBTP","article-title":"Malignant fibrous histiocytoma: between the past and the present.","volume":"132","author":"Al-Agha","year":"2008","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"doi260040r6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2559.2005.02284.x","article-title":"The evolving classification of soft tissue tumours: an update based on the new WHO classification.","volume":"48","author":"Fletcher","year":"2006","journal-title":"Histopathology"},{"issue":"1","key":"doi260040r7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1365-2559.2005.02289.x","article-title":"Classification of pleomorphic sarcomas: where are we now?","volume":"48","author":"Dei Tos","year":"2006","journal-title":"Histopathology"},{"issue":"12","key":"doi260040r8","first-page":"602","article-title":"Malignant fibrous histiocytoma of soft tissue: an abandoned diagnosis.","volume":"33","author":"Randall","year":"2004","journal-title":"Am J Orthop (Belle Mead NJ)"},{"issue":"7","key":"doi260040r9","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1002\/jso.27620","article-title":"Natural history of undifferentiated pleomorphic sarcoma: experience from the US Sarcoma Collaborative.","volume":"129","author":"Makris","year":"2024","journal-title":"J Surg Oncol"},{"issue":"3","key":"doi260040r10","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.soc.2022.03.006","article-title":"Management of myxofibrosarcoma and undifferentiated pleomorphic sarcoma.","volume":"31","author":"Crago","year":"2022","journal-title":"Surg Oncol Clin N Am"},{"issue":"2","key":"doi260040r11","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1200\/JCO.2017.75.3467","article-title":"Biology and management of undifferentiated pleomorphic sarcoma, myxofibrosarcoma, and malignant peripheral nerve sheath tumors: state of the art and perspectives.","volume":"36","author":"Widemann","year":"2018","journal-title":"J Clin Oncol"},{"issue":"11","key":"doi260040r12","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.3390\/cancers17111785","article-title":"Molecular characterization of atypical fibroxanthoma and pleomorphic dermal sarcoma.","volume":"17","author":"Klein","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"8","key":"doi260040r13","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11864-017-0489-6","article-title":"Conception and management of a poorly understood spectrum of dermatologic neoplasms: atypical fibroxanthoma, pleomorphic dermal sarcoma, and undifferentiated pleomorphic sarcoma.","volume":"18","author":"Soleymani","year":"2017","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"doi260040r14","doi-asserted-by":"publisher","first-page":"E65","DOI":"10.12788\/j.sder.2019.008","article-title":"Atypical fibroxanthoma.","volume":"38","author":"Chapman","year":"2019","journal-title":"Semin Cutan Med Surg"},{"issue":"3","key":"doi260040r15","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.det.2019.02.001","article-title":"Atypical fibroxanthoma and pleomorphic dermal sarcoma: updates on classification and management.","volume":"37","author":"Soleymani","year":"2019","journal-title":"Dermatol Clin"},{"issue":"5","key":"doi260040r16","doi-asserted-by":"publisher","DOI":"10.5070\/D3265048789","article-title":"Cutaneous undifferentiated pleomorphic sarcoma is a pleomorphic dermal sarcoma.","volume":"26","author":"Cohen","year":"2020","journal-title":"Dermatol Online J"},{"issue":"12","key":"doi260040r17","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1002\/cncr.28657","article-title":"Sarcoma classification: an update based on the 2013 World Health Organization Classification of Tumors of Soft Tissue and Bone.","volume":"120","author":"Doyle","year":"2014","journal-title":"Cancer"},{"issue":"11","key":"doi260040r18","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1583","article-title":"Pleomorphic dermal sarcoma: clinicopathological features and outcomes from a 5-year tertiary referral centre experience.","volume":"5","author":"Logan","year":"2022","journal-title":"Cancer Rep (Hoboken)"},{"issue":"2","key":"doi260040r21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/ddg.14700","article-title":"S1-guideline atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS).","volume":"20","author":"Helbig","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"doi260040r23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jdcr.2022.09.002","article-title":"Pleomorphic dermal sarcoma of the scalp: review of management and distinguishing features from atypical fibroxanthoma.","volume":"29","author":"Cohen","year":"2022","journal-title":"JAAD Case Rep"},{"issue":"7","key":"doi260040r24","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3390\/genes12070974","article-title":"Clinicopathological and genomic profiles of atypical fibroxanthoma and pleomorphic dermal sarcoma identify overlapping signatures with a high mutational burden.","volume":"12","author":"Ak","year":"2021","journal-title":"Genes (Basel)"},{"issue":"5","key":"doi260040r25","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/ddg.15006","article-title":"Atypical fibroxanthoma and pleomorphic dermal sarcoma\u2014gene expression analysis compared with undifferentiated cutaneous squamous cell carcinoma.","volume":"21","author":"Anders","year":"2023","journal-title":"J Dtsch Dermatol Ges"},{"issue":"1","key":"doi260040r26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.path.2023.06.007","article-title":"Pleomorphic dermal sarcoma.","volume":"17","author":"Saleh","year":"2024","journal-title":"Surg Pathol Clin"},{"issue":"8","key":"doi260040r27","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.3390\/cancers16081452","article-title":"A retrospective review and comprehensive tumour profiling of advanced non-melanomatous cutaneous spindle cell neoplasms treated with immune-checkpoint inhibitors.","volume":"16","author":"McLean","year":"2024","journal-title":"Cancers (Basel)"},{"key":"doi260040r28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.humpath.2020.06.003","article-title":"A genomic survey of sarcomas on sun-exposed skin reveals distinctive candidate drivers and potentially targetable mutations.","volume":"102","author":"Miller","year":"2020","journal-title":"Hum Pathol"},{"issue":"1","key":"doi260040r29","doi-asserted-by":"publisher","first-page":"12516","DOI":"10.1038\/s41598-024-62927-x","article-title":"Proteomic analysis of pleomorphic dermal sarcoma reveals a fibroblastic cell of origin and distinct immune evasion mechanisms.","volume":"14","author":"Klein","year":"2024","journal-title":"Sci Rep"},{"issue":"25","key":"doi260040r30","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition.","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"doi260040r31","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1158\/2159-8290.CD-11-0184","article-title":"High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing.","volume":"2","author":"Wagle","year":"2012","journal-title":"Cancer Discov"},{"issue":"6","key":"doi260040r32","doi-asserted-by":"publisher","first-page":"751","DOI":"10.5858\/arpa.2016-0527-OA","article-title":"Validation of OncoPanel: a targeted next-generation sequencing assay for the detection of somatic variants in cancer.","volume":"141","author":"Garcia","year":"2017","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"doi260040r33","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"issue":"269","key":"doi260040r34","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"issue":"23","key":"doi260040r35","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","article-title":"Analysis and visualization of longitudinal genomic and clinical data from the AACR Project GENIE Biopharma Collaborative in cBioPortal.","volume":"83","author":"de Bruijn","year":"2023","journal-title":"Cancer Res"},{"issue":"14","key":"doi260040r38","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1093\/bioinformatics\/btx149","article-title":"PathwayMapper: a collaborative visual web editor for cancer pathways and genomic data.","volume":"33","author":"Bahceci","year":"2017","journal-title":"Bioinformatics"},{"issue":"1A","key":"doi260040r39","doi-asserted-by":"publisher","first-page":"A68","DOI":"10.5114\/wo.2014.47136","article-title":"The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge.","volume":"19","author":"Tomczak","year":"2015","journal-title":"Contemp Oncol (Pozn)"},{"issue":"6","key":"doi260040r40","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1158\/1078-0432.CCR-14-1773","article-title":"Genomic analysis of metastatic cutaneous squamous cell carcinoma.","volume":"21","author":"Li","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"24","key":"doi260040r41","doi-asserted-by":"publisher","first-page":"6582","DOI":"10.1158\/1078-0432.CCR-14-1768","article-title":"Mutational landscape of aggressive cutaneous squamous cell carcinoma.","volume":"20","author":"Pickering","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"6046","key":"doi260040r42","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1126\/science.1206923","article-title":"Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.","volume":"333","author":"Agrawal","year":"2011","journal-title":"Science"},{"issue":"21","key":"doi260040r43","doi-asserted-by":"publisher","first-page":"5638","DOI":"10.1158\/1078-0432.CCR-20-1899","article-title":"Integrative analysis of pleomorphic dermal sarcomas reveals fibroblastic differentiation and susceptibility to immunotherapy.","volume":"26","author":"Klein","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"doi260040r44","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13569-019-0113-6","article-title":"Genome-wide methylation profiling and copy number analysis in atypical fibroxanthomas and pleomorphic dermal sarcomas indicate a similar molecular phenotype.","volume":"9","author":"Koelsche","year":"2019","journal-title":"Clin Sarcoma Res"},{"issue":"1","key":"doi260040r45","doi-asserted-by":"publisher","first-page":"20438","DOI":"10.1038\/s41598-026-50665-1","article-title":"Mutational profile of atypical fibroxanthoma and pleomorphic dermal sarcoma further expands the spectrum of genomic alterations in rare cutaneous neoplasms.","volume":"16","author":"Caprini","year":"2026","journal-title":"Sci Rep"},{"issue":"4","key":"doi260040r46","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jaad.2021.09.036","article-title":"Surgical excision margins for fibrohistiocytic tumors, including atypical fibroxanthoma and undifferentiated pleomorphic sarcoma: a probability model based on a systematic review.","volume":"87","author":"Jibbe","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"15","key":"doi260040r47","doi-asserted-by":"publisher","first-page":"11015","DOI":"10.1200\/JCO.2019.37.15_suppl.11015","article-title":"Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated\/pleomorphic liposarcoma (LPS): final results of SARC028 expansion cohorts.","volume":"37","author":"Burgess","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"doi260040r48","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.","volume":"19","author":"D\u2019Angelo","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"doi260040r49","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jaad.2025.09.009","article-title":"Efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: results from a pivotal open-label study with a median follow-up of =2 years.","volume":"94","author":"Ruiz","year":"2026","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"doi260040r50","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma.","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"issue":"17","key":"doi260040r51","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMoa2209813","article-title":"Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma.","volume":"387","author":"Gross","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"doi260040r52","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1056\/NEJMoa2502449","article-title":"Adjuvant cemiplimab or placebo in high-risk cutaneous squamous-cell carcinoma.","volume":"393","author":"Rischin","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"doi260040r53","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10","key":"doi260040r54","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s11864-025-01349-x","article-title":"Immunotherapy in the treatment of undifferentiated pleomorphic sarcoma and myxofibrosarcoma.","volume":"26","author":"Wu","year":"2025","journal-title":"Curr Treat Options Oncol"},{"issue":"4","key":"doi260040r55","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s43018-024-00726-z","article-title":"A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity\/truncal undifferentiated pleomorphic sarcoma.","volume":"5","author":"Roland","year":"2024","journal-title":"Nat Cancer"},{"issue":"12","key":"doi260040r56","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1665977","article-title":"First report on two cases of pleomorphic dermal sarcoma successfully treated with immune checkpoint inhibitors.","volume":"8","author":"Klein","year":"2019","journal-title":"Oncoimmunology"},{"issue":"1","key":"doi260040r57","doi-asserted-by":"publisher","DOI":"10.1093\/omcr\/omz138","article-title":"Response to anti-PD1 immunotherapy in patients with metastatic cutaneous sarcoma: case reports and literature review.","volume":"2020","author":"Vieira","year":"2020","journal-title":"Oxf Med Case Reports"},{"key":"doi260040r19","volume-title":"WHO Classification of Tumours of Soft Tissue and Bone","author":"Fletcher","year":"2013","edition":"4th ed"},{"key":"doi260040r20","volume-title":"WHO Classification of Tumours of Soft Tissue and Bone Tumours","author":"WHO Classification of Tumours Editorial Board","year":"2020","edition":"5th ed"},{"key":"doi260040r22","volume-title":"WHO Classification of Skin Tumours","author":"WHO Classification of Tumours Editorial Board","year":"2025","edition":"5th ed"},{"key":"doi260040r36","volume-title":"AACR Project GENIE 18.0-Public Data Guide","author":"AACR","year":"2025"},{"key":"doi260040r37","unstructured":"cBioPortal for Cancer Genomics. Memorial Sloan Kettering Cancer Center. Accessed July 30, 2026. https:\/\/private.cbioportal.mskcc.org\/study\/summary?id=sarcoma_dfci_genie_2026"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2853482\/jamadermatology_neff_2026_oi_260040_1787587923.9435.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:00:27Z","timestamp":1788361227000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2853482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":57,"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2026.3297","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,2]]}}}